Clinical Trial Update: Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid Leukemia [Phase 3]

View source ↗

Summary

Phase 3 trial comparing dasatinib and nilotinib in treatment-naïve chronic myeloid leukemia (chronic phase) has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Sprycel (dasatinib)
• Tasigna (nilotinib)

Snippet

Sponsor: Hamad Medical Corporation | Conditions: Chronic Myeloid Leukemia - Chronic Phase | Phase 3 | Status: TERMINATED